Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

South Africa

- PMLiVE

Pfizer, BioNTech’s COVID-19 vaccine is 95% effective, final analysis shows

Vaccine is over 94% effective in adults over 65 years of age

- PMLiVE

FDA set to publish reviews of data relating to COVID-19 vaccine EUAs

Agency set to publish data as part of 'transparency' efforts

- PMLiVE

Sinovac’s COVID-19 vaccine produces antibody response in mid-stage study

Level of antibodies in vaccinated group lower than recovered COVID-19 patients

- PMLiVE

EU secures 405 million doses of CureVac’s COVID-19 vaccine

CureVac revealed early stage data for its vaccine earlier this month

- PMLiVE

J&J advances COVID-19 vaccine into second phase 3 trial

ENSEMBLE study will enrol 60,000 people worldwide

- PMLiVE

Moderna’s COVID-19 vaccine is 94.5% effective, initial data suggests

The UK government has secured access to five million doses of the vaccine

- PMLiVE

Synairgen’s SNG001 advances into phase 3 COVID-19 trial

UK biotech had initially been testing drug for COPD and asthma

- PMLiVE

CureVac says its COVID-19 vaccine can be stored at standard refrigerator temperature

Shot can also be kept at room temperature for 24 hours

- PMLiVE

GSK, Medicago launch phase 2/3 clinical trials of plant-derived COVID-19 vaccine

Vaccine candidate yielded positive phase 1 results

EU flag

EU agrees on supply deal for 200 million doses of Pfizer, BioNTech’s COVID-19 vaccine

European Commission will have an option to request another 100 million doses

- PMLiVE

Moderna preparing for interim analysis of late-stage COVID-19 vaccine data

The company has accrued enough COVID-19 cases in the trial for interim analysis

- PMLiVE

AZ’s BTK inhibitor Calquence fails in COVID-19 study

Therapy is already approved to treat a number of blood cancers

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links